| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1091: Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments |
|
Medicine details |
|
| Medicine name | Tarlatamab (Imdelltra®) |
| Formulation | 1 mg powder for concentrate and solution for infusion. |
| Reference number | 5340 |
| Indication | For the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/07/2025 |
| NICE guidance | TA1091: Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments |